Simplicity is a virtue.

From Washington, DC,

• Per a DataSpring news release,
  • “The Provider Data Collective, convened by DataSpring, powered by CAQH, today announced a new standard to improve the measurement of provider directory data quality for individual clinicians. It is the first solution from the industry-led coalition bringing together health plans, a health professional organization and an accreditation body to tackle challenges no organization can solve alone. The Collective’s mission is to improve the accuracy and reliability of provider information — clinician data that underpins directories, network operations and other essential health care workflows — so patients, clinicians and health plans can rely on information they trust.
  • Founding organizations of the Collective include Aetna, the American Medical Association, Centene, The Cigna Group, DataSpring, Elevance Health, Horizon Healthcare Services, Inc., Humana, the National Committee for Quality Assurance (NCQA) and UnitedHealthcare. * * *
  • “Inaccurate provider data can create real barriers across healthcare. Patients struggle to confirm whether a clinician is in-network, providers face delays joining networks and seeing patients, and care teams often lack the reliable information needed to coordinate care,” said Tim Kaja, executive vice president of UnitedHealth Group Enterprise Services and board chair of DataSpring. “While CMS established a method to measure provider data accuracy, inconsistent application made it difficult to establish a common baseline for improvement of provider data quality across the industry. The Collective aligned the industry around a shared framework — a more consistent way to measure data quality, identify gaps and track progress.”
  • “The data quality measurement standard creates a foundation for tracking and improving provider data quality across the ecosystem. It also allows this industry-led work to inform regulatory activity as policymakers seek to modernize provider data infrastructures. With that foundation in place, the Collective will next focus on other industry challenges, including how accepting-new-patients status is determined, updated and reflected in directories to improve accuracy and patient access.”

• Modern Healthcare reports,
  • “The Centers for Medicare and Medicaid Services has gained unprecedented authority to remove providers, insurers and suppliers from federal health programs over fraud concerns.
  • “Health and Human Services Secretary Robert F. Kennedy Jr. published a notice Tuesday announcing he is officially delegating those powers, which had been solely held by the HHS Office of Inspector General, to CMS.”
  • “The two-page document formalizes remarks Kennedy made at a news conference in July. “Both CMS and the Office of Inspector General will be able to use that authority to remove bad actors from federal healthcare programs and, in many cases, permanently ban them from returning,” Kennedy said at the time.
  • “The policy shift gives CMS a significant enforcement tool as the agency toughens up its oversight and fraud detection strategy.”

• Bloomberg Law adds,
  • “US Health Secretary Robert F. Kennedy Jr.’s proposal to pay doctors to collect information about vaccine injuries drew criticism from medical groups over concerns it would create perverse incentives and a perception of causality not based on evidence.
  • “The idea is one pillar of the Department of Health and Human Services’ new vaccine injury research project formally announced on Thursday, three days after agency leaders secretly met at the National Institutes of Health to pitch it. 
  • “The proposal to compensate Medicare providers was tucked into a wide-ranging physician payment rule expected to be finalized next month as part of an annual rulemaking process.”

• Beckers Hospital Review relates,
  • “Four House lawmakers, Reps. Rob Bresnahan, R-Pa., Debbie Dingell, D-Mich., Tracey Mann, R-Kan., and Lois Frankel, D-Fla., have introduced bipartisan legislation that would pause HRSA’s 340B rebate model pilot.” * * *
  • “The bill, the 340B Rebate Model Delay Act, would require drugmakers to provide 340B discounts upfront at the time of purchase from Jan. 1, 2027, through Dec. 31, 2028. It would also bar the use of federal funds to implement the rebate pilot or a substantially similar program during that period.
  • “The pause would give Congress time to consider broader 340B reform, including the SECURE 340B Act in the House and the SUSTAIN 340B Act in the Senate, according to an Oct. 9 statementfrom Advocates for Community Health. The group said health centers could be forced to cut services if they have to absorb full drug costs while awaiting rebates.”

• Per a HRSA news release,
  • “The Health Resources and Services Administration (HRSA) today announced $12.7 million in Fiscal Year 2026 awards through the Maternal Produce Prescription Program (MP3) to help pregnant and postpartum women and their families in low-income and medically underserved communities access healthy foods.
  • “MP3 provides produce prescriptions or vouchers and nutrition education to help pregnant and postpartum women and their families access fruits and vegetables. The program strengthens partnerships among healthcare providers, community-based organizations, and local food systems and aims to increase fruit and vegetable consumption, improve household food security, and improve maternal and birth outcomes.”

From the U.S. Office of Personnel Management front,

• Federal News Network discusses “FEHB and Medicare: Understanding how they work together in retirement.”

• FedScoop adds, “OPM updates terms of service for USAJobs data following user confusion.
  • “The human capital agency again updated terms for its USAJobs application programming interface to reflect that the data is public and expressly allow analysis.” * * *
  • “In new updated terms released Friday, the agency enshrined its clarifications into its policy.
  • “The terms now state that information from the API is public data and as such, can be “copied, stored, reformatted, adapted, analyzed, published, redistributed, and used for lawful commercial or noncommercial purposes” without prior approval from OPM. 
  • “They also include language protecting analysis, while making it clearer that fraudsters are the target. Under the terms, API users can “modify, summarize, analyze, or combine” the public data, but may not falsely represent the information. ” * * *
  • “In response, the user community cheered the update.”

From the U.S. Food and Drug Administration front,

• CBS News reports,
  • “The Food and Drug Administration received reports in recent months that two people died after taking bootleg versions of an experimental weight-loss drug, according to documents reviewed by CBS News.
  • “The reports link the deaths to products claiming to be retatrutide, a drug being developed by Eli Lilly that hasn’t been approved by the FDA. Federal law prohibits the commercial sale of unapproved drugs, but that hasn’t stopped vendors from selling imitation versions of the experimental drug online at a scale with no modern precedent. 
  • “The cases appear to be the first public accounts in the U.S. alleging that unauthorized use of retatrutide — or products claiming to contain it — played a role in a patient’s death, though the details aren’t verified and it is unclear whether the drug was to blame.” * * *
  • “CBS News was not able to independently verify the information included in the reports, which were obtained under the U.S. Freedom of Information Act and redacted by the agency to remove details that could identify the people mentioned in them. They are part of an emerging picture of potential side effects from a drug that many people are obtaining from unregulated sellers and with minimal to no medical supervision.
  • “America’s Poison Centers, a nonprofit, has tallied a steady increase in reported exposures to retatrutide since it began tracking them late last year, which is common for a newly monitored drug. The centers logged 862 exposures to retatrutide in the three months ending in September, up from 460 in the three months prior and 249 in the first three months of 2026.” * * *
  • “In a statement, Eli Lilly said that the reported deaths “make clear the two individuals were taking black-market retatrutide.” The company said it has found suspect products “with too much, too little, or the wrong active ingredient,” along with contaminants that “can put patients at serious risk.”
  • “Eli Lilly is taking legal action against companies selling bootleg versions of retatrutide, claiming that people will associate bad reactions to them with its product, “poisoning the well for the future of retatrutide medicines.” 
    
• DI Cardiology tells us,
  •  “Endovascular Engineering (E2) has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for both the Hēlo Thrombectomy System and Hēlo Return (Blood Return System).
  • “Hēlo, which is a physician-inspired, purpose-built thrombectomy platform for treating pulmonary embolism, leverages a unique design that consistently led to efficient single-pass procedures in the Engulf IDE study. The platform showcased the highest reported clot reduction and the lowest estimated blood loss across all PE Thrombectomy IDE studies.¹ 
  • “While Engulf provided important clinical validation of the platform’s capabilities, the FDA clearances represent a significant step forward as E2 brings its innovative platform to a broad range of physicians and patients. PE remains a leading cause of cardiovascular death and disability, and there is growing demand for mechanical solutions that support clot removal while reducing procedural complexity and right heart strain.”

• MassDevice adds,
  • “BridgeSource Medical obtained de novo clearance from the FDA for its handheld cardiac implant identifier, designed to help emergency department clinicians quickly identify a patient’s hardware brand.
  • “According to the Austin, Texas–based company, about half the time a patient enters the ER they don’t know, can’t communicate or aren’t carrying the wallet card listing the specific brand of their pacemaker or implanted defibrillator. This causes delays in triage and treatment — with different approaches being needed for each manufacturer — and clinicians often have to resort to an X-ray to determine the type of device.
  • “BridgeSource’s SmartRead system can be used by frontline healthcare workers to identify an implant within 20 seconds. It works by mimicking the initial communication pings sent by the programming wands from each major implant manufacturer and waiting for a response, including devices from Abbott, Biotronik, Boston Scientific, Medtronic and MicroPort.”

From the public health and medical / Rx research front,

• JACC offers information about “Cardiovascular Disease Mortality [CVD] by County, Race and/or Ethnic Population, United States, 2000-2019.”
  • “While declining CVD mortality reflects meaningful clinical and public health progress, persistent and pervasive disparities demand solutions-oriented, place-informed research to drive further progress. Critically, these pre-Covid data establish a baseline essential for isolating Covid-era–attributable shifts from preexisting trends. These granular county-level data stratified by CVD cause, race, and/or ethnicity offer a scalable, repeatable framework for agencies to tailor health interventions and rigorously track disparities over time.”

• Health Day adds,
  • “Monitoring blood pressure at home could help prevent a life-altering injury for some seniors, a new study warns.
  • “Seniors older than 78 with “masked” high blood pressure have a 70% higher risk of falls than those who’ve been properly diagnosed, according to results presented at the American Heart Association’s annual meeting on hypertension.
  • “Researchers said masked high blood pressure involves seniors’ readings appearing normal at a doctor’s office but consistently high at home.
  • “These findings highlight that, in addition to office blood pressure measurement, home blood pressure readings can be an important way to identify hidden home high blood pressure and risk of falls in older adults,” lead investigator Frances Wang said in a news release. She is a researcher at Beth Israel Deaconess Medical Center in Boston.
  • “Changes in blood pressure can increase fall risk by causing dizziness or fainting, according to the American Heart Association (AHA).”

• Per a National Institutes of Health news release,
  • “A scientific team funded by the National Institutes of Health (NIH) has built a super intelligence (SI)-based interface that enables real-time communication between patients and epilepsy monitoring devices. As part of a small clinical study at the University of Pennsylvania, Philadelphia, patients used a smart-phone application to inquire about their own physiological data and received accurate information in response. Conversely, the system learned from patient feedback to improve seizure detection, ultimately reducing its false alarms by about 80%. 
  • “This proof-of-concept showcases a technology with the exciting potential to shift management of epilepsy and possibly other diseases in a more adaptive direction that puts patients in the driver’s seat,” said Amy Bany Adams, Ph.D., acting director of the NIH’s National Institute of Neurological Disorders and Stroke (NINDS).” 

• Radiology Business reports,
  • “Alterations in brain connectivity may be associated with anxiety in adolescents, according to new research. 
  • “Published in Imaging Neuroscience, the findings implicate brain circuits connecting the cerebellum, amygdala and thalamus in adolescent anxiety. Experts involved in the study are hopeful that their research could help guide personalized approaches to youth mental health care in the future. 
  • “Precision psychiatry is likely to play an important role in future mental health care,” noted study leader Caterina Stamoulis, PhD, principal investigator in Boston Children’s Computational Neuroscience Laboratory. “In this study, we have identified specific circuits that are implicated in anxiety, which could become the targets of precision interventions to improve short- and longer-term mental health outcomes in youth.” * * *
  • “While the findings are promising and offer scientists a deeper level of understanding of the underlying mechanisms of anxiety disorders in adolescents, additional research will be needed to determine whether the imaging markers can predict individual outcomes or help clinicians select and evaluate targeted interventions. 
  • “Read more here.” 

• BioPharma Dive relates,
  • “An experimental mRNA cancer immunotherapy from BioNTech failed to delay tumor progression in a late-stage study in a form of head and neck cancer, the company said Tuesday.
  • “According to BioNTech, a combination of its treatment BNT 113 and the widely used drug Keytruda didn’t extend progression-free survival at an interim data check. The trial is testing the dual regimen against Keytruda alone as a first-line treatment in head and neck squamous cell carcinoma that’s driven by a high-risk strain of human papillomavirus. 
  • “A data monitoring committee encouraged BioNTech to continue the trial to determine whether the BNT 113-Keytruda regimen can meet the study’s other main objective by extending survival. Should it do so, BioNTech could still claim success. The early results “support continued evaluation” and show the drug combination is “engaging its intended therapeutic mechanism,” said co-founder and Chief Medical Officer Özlem Türeci.”
• and
  • “Bristol Myers Squibb said Monday that its experimental lung disease drug admilparant succeeded in a Phase 3 trial in idiopathic pulmonary fibrosis, significantly slowing the decline of study participants’ breathing capacity when compared to a placebo over the course of a year.
  • “However, trial investigators only found a clear benefit among those who received a 60 milligram dose of admilparant. A 120 milligram dose was associated with an impact on disease progression, but the difference didn’t meet the threshold for statistical significance, the company said.
  • “The failure of the high-dose arm is “confounding and requires further explanation,” RBC Capital Markets analyst Trung Huynh wrote in a client note. Bristol Myers previously made certain trial revisions that sparked liver-related safety concerns about admilparant, too, although the company said Monday that the drug “demonstrated a well-tolerated safety profile” and treatment-related study discontinuations were similar between study groups.”

From the U.S. healthcare business and artificial intelligence front,

• The Wall Street Journal reports,
  • “UnitedHealth UNH Group reported earnings that came in above analysts’ expectations and again raised its projection for the year, as the healthcare company continued charting a financial turnaround.
  • “The announcement comes more than a year after Chief Executive Stephen Hemsley returned to the top job, promising major changes after a meltdown that cut the company’s valuation by hundreds of billions of dollars.
  • “For the third quarter of 2026, UnitedHealth reported net income of $4.11 billion, or $4.56 a share. That compared with net income of $2.35 billion, or $2.59 a share, a year earlier.” * * *
  • “UnitedHealthcare, the insurance arm, reported a medical-loss ratio of 88.4%, a closely watched number that represents the share of premiums spent on medical costs. The FactSet consensus projection was 89.7%.”
• and
  • “Johnson & Johnson JNJ is “leaning” toward spinning out the hips-and-knees business that the company has been looking to hive off, Chief Financial Officer Joseph Wolk said.
  • “We think the best value creation at this moment in time for J&J shareholders is to spin it straight out,” Wolk said in an interview. The company talked with private-equity firm Apollo Global Management about a roughly $20 billion sale, The Wall Street Journal has reported.
  • “Wolk made the remarks as J&J said its sales grew a healthy 5.9% in the recent quarter to $25.4 billion, and the company raised its forecast for full-year performance.
  • “Sales of prescription drugs powered J&J’s quarterly results. The company’s medical-device business didn’t grow as much. While acknowledging the medical-device unit needed work, the company said it was on track to surpass $100 billion in yearly sales.
  • “J&J is considered a bellwether for the healthcare industry because its portfolio spans so many different products. Its results show the enduring demand for medical treatment, as other industries grapple with consumers tightening spending because of higher fuel and other costs.”
• and
  • “Roche ROP Holding struck a deal with China’s Rona Therapeutics to license worldwide rights to an experimental therapy for obesity and metabolic diseases for up to $1.16 billion, moving to bolster its portfolio with a new weight-loss approach.
  • “Under the agreement, Shanghai-based Rona will get upfront and near-term payments of up to $100 million and be eligible to receive an extra $1.06 billion subject to reaching development, regulatory and commercial goals, as well as royalties on potential sales, Rona said Tuesday.
  • “Roche has sought to build and expand a portfolio of weight-loss drugs in recent years, joining a growing group of drugmakers vying to challenge Eli Lilly and Novo Nordisk. It completed in 2024 its $2.7 billion purchase of U.S. obesity drug developer Carmot Therapeutics and entered into an up to $5.3 billion licensing deal with Denmark’s Zealand Pharma to jointly develop a different kind of weight-loss medicine last year.”

• Beckers Payer Issues relates,
  • “Humana has agreed to form a new joint venture with investment management firm BlackRock to own and operate nearly 150 CenterWell Senior Primary Care clinics, replacing CenterWell’s existing joint ventures with private equity firm Welsh, Carson, Anderson & Stowe. 
  • “Funds and accounts managed by HPS Investment Partners, part of BlackRock, will acquire Welsh Carson’s equity stake, valued at about $2.8 billion, according to an Oct. 13 Humana news release. BlackRock will hold majority ownership, while CenterWell will retain a minority stake and continue managing the clinics.
  • “Unlike the previous agreements, the new deal does not give BlackRock the right to force Humana to buy out its stake. Humana said removing that obligation will significantly reduce liabilities on its balance sheet and lower its cost of capital.
  • “Beginning in 2028, CenterWell can buy clinics from the joint venture, according to the release. If CenterWell has not acquired all of them by the end of 2033, BlackRock can exit through a sale of the remaining clinics, with CenterWell holding the right to make the first offer.”
• and
  • “Centene will launch its National Performance-Based Gold Card Program in November.
  • “Gold carding aims to streamline prior authorization, reducing requirements for trusted providers. The program will first be available to more than 160,000 qualifying providers across the country for some outpatient services. Eligibility is determined by approval history, documentation quality, medical policy compliance and adherence to regulatory requirements. The insurer anticipates expanding the program to other service types and providers in the future.
  • “Centene COO Susan Smith said the program “was shaped through deep collaboration with providers, ensuring its review process is grounded in the real-world needs of those delivering care every day.” Providers spanning 24 states anonymously contributed feedback to inform the program, according to an Oct. 13 news release.” * * *
  • “In recent years, UnitedHealthcare and Humana have also announced gold card programs. Centene’s update comes as prior authorization reforms pick up steam.”

• Per a Healthcare Cost Institute news release,
  • “Health care spending for people with employer-sponsored insurance reached $6,743 per person in 2023, according to the nonprofit Health Care Cost Institute’s latest Health
  • “Care Cost and Utilization Report. Per-person spending rose 18.8% from 2019 to 2023, with higher prices, not greater use of care, driving most of the increase.
  • “From 2022 to 2023, spending per person grew 6.5% while utilization was essentially flat. Average prices rose 6.7% that year, continuing a five-year pattern of annual price growth.
  • “Prices are the primary force behind high health care costs,” said Katie Martin, HCCI president and CEO. “Employers, policymakers and other decisionmakers need to focus on price growth to make care more affordable for people and families with job-based coverage.”

• Beckers Hospital Review tells us,
  • “Hospital margins fell in August as financial pressures mounted and the share of hospitals operating at a loss is growing, according to Kaufman Hall’s [Augut 2026] “National Hospital Flash Report,” released Oct. 13.
  • “The report is based on August 2026 financial performance data from 1,300 hospitals, provided by Strata Decision Technology. The hospitals represent all regions of the country and range from small to large institutions.
  • “The average hospital margin has declined steadily since hitting 5.6% in June. The average fell to 1.8% in August, down from 3.8% in July. The year-to-date average operating margin dropped from 3.8% in July to 2.5% in August.
  • “Mounting financial challenges from increasing bad debt and charity care, payer mix erosion and rising expenses may prompt hospitals to strengthen enterprise margin preservation efforts,” the report said.
  • “About 43% of hospitals are operating in the red, up from 33% before the COVID-19 pandemic. Hospitals have experienced many challenges in the last six years, including staffing shortages, supply cost increases, tech and AI spend and more.”

• Per a Vizient news release,
  • “The sustained momentum in hospital and health system M&A activity has shown that health systems continue to advance active positioning and portfolio management, with 16 hospital and health system transactions announced in Q3 2026. The 16 announced transactions in Q3 2026 (Figure 1) are on par with what we saw in Q3 2025. As deal volume continued, mega mergers also continued to make waves across the industry. For the third consecutive quarter, multiple mega mergers—transactions in which the smaller party had annual revenue exceeding $1 billion—were announced, along with several transactions that fell just shy of the $1 billion threshold.
  • “The size of these transactions kept the average seller size elevated relative to recent year-end figures, continuing to suggest that M&A activity is increasingly involving larger organizations opting to partner with even larger ones.
  • “Divestitures of specific health system assets represented five of the 16 announced transactions in Q3 2026.”

• Beckers Payer Issues notes,
  • “CMS’ 2.5% efficiency adjustment cut work relative value units on about 7,700 non-time-based codes starting Jan. 1. It was a percentage cut that came with a conversion factor increase, so the dollar effect is easy to miss. For physicians paid per wRVU, it runs from nothing to more than $13,000 a year, depending on specialty.” * * *
  • “The Medical Group Management Association and consulting firm PYA have flagged procedural and imaging-heavy groups on formula-based wRVU incentives as the most exposed. MGMA also noted exposure for groups whose commercial contracts or benchmarks are tied to wRVU counts.”
    
• MedCity News informs us,
  • “Outro, a neuroscience-based platform, announced last week that it raised $7 million in pre-seed and seed funding.
  • “The New York-based company helps patients discontinue psychiatric medications. Patients visit with clinicians trained in safe deprescribing and receive access to personalized tapering plans. They also gain access to compounded medication doses.
  • “Roughly 1 in 6 Americans take antidepressants. There are tens of millions of people on these drugs, yet no science-based way to get off safely. … Outro is the off-ramp that should have been built from the beginning. We want getting off a medication to be as supported as getting on it – arguably even more,” said Brandon Goode, co-founder and CEO of Outro.”

• Beckers Health IT points out,
  • “The American Medical Association released a governance framework Oct. 13 for agentic AI that takes on clinical functions. The framework says an AI system’s clinical authority must be earned through evidence and maintained through ongoing performance.
  • “The AMA said an AI system’s authority and oversight can change as its evidence, performance, risk or underlying technology changes.”